Chemomab Therapeutics Ltd. Logo

Chemomab Therapeutics Ltd.

Clinical-stage biotech developing therapeutics for fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):
US16385C1045 (+1 more)
LEI:
Country:
United States of America
Address:
KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-21 07:15
6-K
English ZIP 84.0 KB
2025-08-22 18:05
6-K
English ZIP 9.2 KB
2025-08-14 10:01
6-K
English ZIP 702.5 KB
2025-08-11 15:04 English ZIP 7.9 KB
2025-07-25 18:33
6-K
English ZIP 945.4 KB
2025-07-25 18:05
424B5
English ZIP 1.6 MB
2025-07-01 18:05
6-K
English ZIP 9.1 KB
2025-06-23 19:06 English ZIP 16.4 KB
2025-05-27 18:05
6-K
English ZIP 1.7 MB
2025-05-15 10:00
6-K
English ZIP 86.6 KB
2025-04-15 10:00
6-K
English ZIP 78.5 KB
2025-04-10 19:25 English ZIP 10.1 KB
2025-04-04 19:17
20-F
English ZIP 7.0 MB
2025-03-27 09:30
6-K
English ZIP 1.0 MB
2025-03-20 18:14
6-K
English ZIP 29.8 KB

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alzinova AB Logo
Clinical-stage biopharma developing immunotherapies for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops and commercializes therapeutics to improve cardiovascular health.
United States of America
AMRN
AMGEN INC Logo
A biotechnology company developing human therapeutics for serious illnesses.
United States of America
AMGN
Industrial biotechnology company specializing in specialty enzymes and proteins.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Biotechnology company developing therapies for rare genetic and devastating diseases.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Specialty manufacturer of high-purity chiral amino acids and their derivatives.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops, manufactures, and distributes generic and specialty pharmaceuticals.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops, manufactures, and markets technically challenging medications.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Develops therapies for neurodegenerative diseases and other unmet medical needs.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Biopharmaceutical firm developing boron-based drugs for infectious diseases.
United States of America
ANTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.